A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice

Alberto Gobbi, Cristina Di Berardino, Eugenio Scanziani, Angela Garofalo, Anna Rivolta, Giovanna Fontana, Alessandro Rambaldi, Raffaella Giavazzi, Andrea Biondi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study describes a new human acute lymphoblastic leukemia (ALL) cell line (ALL-PO) with the t(411) translocation established in SCID mice. The ALL-PO line can be maintained by serial transplant in SCID mice with stable immunophenotypic, molecular and karyotypic features. After intravenous (i.v.) injection ALL-PO spread systemically involving the hematopoietic organs and the central nervous system (CNS) of all mice. The homing and the progression of the disease are evaluated by histological analysis and reverse-transcriptase polymerase chain reaction (PT-POP) amplification of the t(4;11) translocation in the bone marrow, spleen and CNS of SCID mice at different times after engraftment. Occult leukemia was detectable by PCR in the bone marrow of SCID mice as early as three days after the i.v. injection of leukemic cells whereas the first signs of involvement of the spleen and CNS appeared after 14 days; after 24 days all the mice were euthanized because they were moribund and the bone marrow, spleen and CNS showed ample infiltration by leukemic cells. The sensitivity to conventional chemotherapy was tested in this model. ALL-PO in SCID mice did not respond to treatment with vincristine or idarubicin but cyclophosphamide (150 mg kg-1 i.v., single injection) significantly increased the survival of the mice. The efficacy of such a treatment was more evident when cyclophosphamide was given in the early stages of the disease (detectable only by molecular analysis) but much less effective when the drug was administered when the disease could be detected by conventional histological analysis. The biological behavior and molecular characteristics of ALL-PO make it a good model for studying novel therapeutic strategies for a better control of minimal residual disease.

Original languageEnglish
Pages (from-to)1107-1114
Number of pages8
JournalLeukemia Research
Volume21
Issue number11-12
DOIs
Publication statusPublished - Nov 1997

Fingerprint

SCID Mice
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System
Intravenous Injections
Spleen
Bone Marrow
Cyclophosphamide
Leukemic Infiltration
Idarubicin
Vincristine
Reverse Transcriptase Polymerase Chain Reaction
Disease Progression
Leukemia
Therapeutics
Transplants
Drug Therapy
Cell Line
Polymerase Chain Reaction
Pharmaceutical Preparations

Keywords

  • ALL
  • Leukemia
  • Minimal residual disease
  • SCID mice
  • t(4;11) translocation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Gobbi, A., Di Berardino, C., Scanziani, E., Garofalo, A., Rivolta, A., Fontana, G., ... Biondi, A. (1997). A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice. Leukemia Research, 21(11-12), 1107-1114. https://doi.org/10.1016/S0145-2126(97)00092-1

A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice. / Gobbi, Alberto; Di Berardino, Cristina; Scanziani, Eugenio; Garofalo, Angela; Rivolta, Anna; Fontana, Giovanna; Rambaldi, Alessandro; Giavazzi, Raffaella; Biondi, Andrea.

In: Leukemia Research, Vol. 21, No. 11-12, 11.1997, p. 1107-1114.

Research output: Contribution to journalArticle

Gobbi, A, Di Berardino, C, Scanziani, E, Garofalo, A, Rivolta, A, Fontana, G, Rambaldi, A, Giavazzi, R & Biondi, A 1997, 'A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice', Leukemia Research, vol. 21, no. 11-12, pp. 1107-1114. https://doi.org/10.1016/S0145-2126(97)00092-1
Gobbi, Alberto ; Di Berardino, Cristina ; Scanziani, Eugenio ; Garofalo, Angela ; Rivolta, Anna ; Fontana, Giovanna ; Rambaldi, Alessandro ; Giavazzi, Raffaella ; Biondi, Andrea. / A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice. In: Leukemia Research. 1997 ; Vol. 21, No. 11-12. pp. 1107-1114.
@article{668a5f02d2974e67a3ad418845de2f7f,
title = "A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice",
abstract = "This study describes a new human acute lymphoblastic leukemia (ALL) cell line (ALL-PO) with the t(411) translocation established in SCID mice. The ALL-PO line can be maintained by serial transplant in SCID mice with stable immunophenotypic, molecular and karyotypic features. After intravenous (i.v.) injection ALL-PO spread systemically involving the hematopoietic organs and the central nervous system (CNS) of all mice. The homing and the progression of the disease are evaluated by histological analysis and reverse-transcriptase polymerase chain reaction (PT-POP) amplification of the t(4;11) translocation in the bone marrow, spleen and CNS of SCID mice at different times after engraftment. Occult leukemia was detectable by PCR in the bone marrow of SCID mice as early as three days after the i.v. injection of leukemic cells whereas the first signs of involvement of the spleen and CNS appeared after 14 days; after 24 days all the mice were euthanized because they were moribund and the bone marrow, spleen and CNS showed ample infiltration by leukemic cells. The sensitivity to conventional chemotherapy was tested in this model. ALL-PO in SCID mice did not respond to treatment with vincristine or idarubicin but cyclophosphamide (150 mg kg-1 i.v., single injection) significantly increased the survival of the mice. The efficacy of such a treatment was more evident when cyclophosphamide was given in the early stages of the disease (detectable only by molecular analysis) but much less effective when the drug was administered when the disease could be detected by conventional histological analysis. The biological behavior and molecular characteristics of ALL-PO make it a good model for studying novel therapeutic strategies for a better control of minimal residual disease.",
keywords = "ALL, Leukemia, Minimal residual disease, SCID mice, t(4;11) translocation",
author = "Alberto Gobbi and {Di Berardino}, Cristina and Eugenio Scanziani and Angela Garofalo and Anna Rivolta and Giovanna Fontana and Alessandro Rambaldi and Raffaella Giavazzi and Andrea Biondi",
year = "1997",
month = "11",
doi = "10.1016/S0145-2126(97)00092-1",
language = "English",
volume = "21",
pages = "1107--1114",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "11-12",

}

TY - JOUR

T1 - A human acute lymphoblastic leukemia line with the t(4;11) translocation as a model of minimal residual disease in SCID mice

AU - Gobbi, Alberto

AU - Di Berardino, Cristina

AU - Scanziani, Eugenio

AU - Garofalo, Angela

AU - Rivolta, Anna

AU - Fontana, Giovanna

AU - Rambaldi, Alessandro

AU - Giavazzi, Raffaella

AU - Biondi, Andrea

PY - 1997/11

Y1 - 1997/11

N2 - This study describes a new human acute lymphoblastic leukemia (ALL) cell line (ALL-PO) with the t(411) translocation established in SCID mice. The ALL-PO line can be maintained by serial transplant in SCID mice with stable immunophenotypic, molecular and karyotypic features. After intravenous (i.v.) injection ALL-PO spread systemically involving the hematopoietic organs and the central nervous system (CNS) of all mice. The homing and the progression of the disease are evaluated by histological analysis and reverse-transcriptase polymerase chain reaction (PT-POP) amplification of the t(4;11) translocation in the bone marrow, spleen and CNS of SCID mice at different times after engraftment. Occult leukemia was detectable by PCR in the bone marrow of SCID mice as early as three days after the i.v. injection of leukemic cells whereas the first signs of involvement of the spleen and CNS appeared after 14 days; after 24 days all the mice were euthanized because they were moribund and the bone marrow, spleen and CNS showed ample infiltration by leukemic cells. The sensitivity to conventional chemotherapy was tested in this model. ALL-PO in SCID mice did not respond to treatment with vincristine or idarubicin but cyclophosphamide (150 mg kg-1 i.v., single injection) significantly increased the survival of the mice. The efficacy of such a treatment was more evident when cyclophosphamide was given in the early stages of the disease (detectable only by molecular analysis) but much less effective when the drug was administered when the disease could be detected by conventional histological analysis. The biological behavior and molecular characteristics of ALL-PO make it a good model for studying novel therapeutic strategies for a better control of minimal residual disease.

AB - This study describes a new human acute lymphoblastic leukemia (ALL) cell line (ALL-PO) with the t(411) translocation established in SCID mice. The ALL-PO line can be maintained by serial transplant in SCID mice with stable immunophenotypic, molecular and karyotypic features. After intravenous (i.v.) injection ALL-PO spread systemically involving the hematopoietic organs and the central nervous system (CNS) of all mice. The homing and the progression of the disease are evaluated by histological analysis and reverse-transcriptase polymerase chain reaction (PT-POP) amplification of the t(4;11) translocation in the bone marrow, spleen and CNS of SCID mice at different times after engraftment. Occult leukemia was detectable by PCR in the bone marrow of SCID mice as early as three days after the i.v. injection of leukemic cells whereas the first signs of involvement of the spleen and CNS appeared after 14 days; after 24 days all the mice were euthanized because they were moribund and the bone marrow, spleen and CNS showed ample infiltration by leukemic cells. The sensitivity to conventional chemotherapy was tested in this model. ALL-PO in SCID mice did not respond to treatment with vincristine or idarubicin but cyclophosphamide (150 mg kg-1 i.v., single injection) significantly increased the survival of the mice. The efficacy of such a treatment was more evident when cyclophosphamide was given in the early stages of the disease (detectable only by molecular analysis) but much less effective when the drug was administered when the disease could be detected by conventional histological analysis. The biological behavior and molecular characteristics of ALL-PO make it a good model for studying novel therapeutic strategies for a better control of minimal residual disease.

KW - ALL

KW - Leukemia

KW - Minimal residual disease

KW - SCID mice

KW - t(4;11) translocation

UR - http://www.scopus.com/inward/record.url?scp=0031452871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031452871&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(97)00092-1

DO - 10.1016/S0145-2126(97)00092-1

M3 - Article

VL - 21

SP - 1107

EP - 1114

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11-12

ER -